We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| GE Aerospace | NYSE:GE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -5.09 | -3.33% | 147.85 | 153.525 | 146.78 | 153.33 | 9,565,084 | 23:43:57 |
From Apr 2021 to Apr 2024
By Michael Dabaie
General Electric Co.'s healthcare business said it acquired Zionexa, a company focused on in-vivo oncology and neurology biomarkers.
GE Healthcare said it aims to develop and bring to market Zionexa's pipeline biomarkers, as well as the recently Food and Drug Administration-approved positron emission tomography imaging agent, Cerianna. Cerianna is used as an adjunct to biopsy for the detection of estrogen receptor positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer.
Zionexa was formed in 2018 and headquartered in Aubiere, France. The company employs 24 people in France and the U.S., all of whom will transfer to GE Healthcare. GE Healthcare said it will hire about 70 new dedicated employees within the company's U.S. Pharmaceutical Diagnostics team.
Financial terms of the acquisition aren't being disclosed, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 06, 2021 09:36 ET (13:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GE Aerospace Chart |
1 Month GE Aerospace Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
